Depomed (DEPO) Withdraws Two Suits Against Gralise ANDA Filers

Article Related Press Releases (1) Stock Quotes (2) Comments (0)

Depomed, Inc. (NASDAQ: DEPO) announced that its lawsuits against two filers of Abbreviated New Drug Applications (ANDAs) for Gralise® (gabapentin) have been dismissed. Watson Laboratories (NYSE: WPI) has withdrawn its Gralise ANDA. Par Pharmaceutical has amended its Gralise ANDA and is no longer seeking approval of the ANDA prior to the expiration of Depomed's patents listed for Gralise in the FDA publication commonly known as the Orange Book. As a result, the U.S. District Court for the District of New Jersey has granted the parties' request for dismissal of Depomed's lawsuits against Watson and Par for infringement of Depomed's Gralise patents. As previously disclosed, in October 2012 Depomed's patent lawsuit against Impax was dismissed following Impax's withdrawal of its Gralise ANDA.

Depomed's patent litigation against the remaining three Gralise ANDA filers continues in the U.S. District Court for the District of New Jersey.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Sanofi (SNY), Regeneron (REGN) Report Publication of Positive Dupilumab Phase 2a Data
• J. C. Penney (JCP) Reports Successful Early Tender of 7 1/8% Notes
• FX Energy (FXEN) Victorious in Tuchola-3K Well Testing

Create E-mail Alert Related Categories

Corporate News, FDA

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?